Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. (Nasdaq: TKNO) is a producer of critical reagents for the life sciences industry, with news flow that reflects its role in supporting therapies, vaccines, molecular diagnostics, and cell therapies. Company updates often highlight performance across its Lab Essentials and Clinical Solutions product groupings, as well as developments in its manufacturing platform and collaborations.
Investors and observers following TKNO news can expect regular earnings announcements and related commentary on revenue trends, gross margin, operating expenses, and non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow. These updates are typically furnished through press releases and accompanying Form 8-K filings that discuss quarterly and full-year financial results and provide revenue breakdowns by Lab Essentials, Clinical Solutions, and Other categories.
Teknova’s news also includes product and partnership announcements. A notable example is its collaboration with Pluristyx, Inc. on the PluriFreeze cryopreservation system, where Teknova serves as the exclusive manufacturer and distributor in the United States and Canada. Press releases describe how this system is intended to streamline the manufacture of next-generation allogeneic cell therapies through synthetic, animal-origin-free cryopreservation and wash media.
Additional news items cover guidance for upcoming periods, descriptions of the company’s participation in investor conferences, and reminders about scheduled earnings calls and webcasts. For readers interested in how a life science reagents supplier communicates its financial performance, product evolution, and strategic collaborations, the TKNO news feed provides an ongoing record of Teknova’s public disclosures and corporate milestones.
Alpha Teknova (Nasdaq: TKNO) announced an Early Access Program for two innovative products aimed at enhancing gene therapy processes: an Anion Exchange Buffer Screening Kit and a Functional Reporter Assay. These products are still in development and focus on improving AAV therapy workflows. Additionally, the company revealed it will launch a WFI Quality Water product available online in November 2022. The goal is to streamline development and increase product purity for AAV gene therapy developers.
Alpha Teknova, a leading provider of critical reagents, announced that CEO Stephen Gunstream will present at the 2022 Cell & Gene Meeting on the Mesa on October 12, 2022. The presentation, scheduled for 5:45 p.m. PT in Carlsbad, California, will focus on the company's growth strategy and updates in their gene therapy product development. This three-day conference, organized by the Alliance for Regenerative Medicine, gathers industry executives to discuss advancements in cell and gene therapies. A live broadcast will be available for registered participants.
Alpha Teknova, Inc. (Nasdaq: TKNO), a leader in critical reagents for drug therapies and vaccines, will join the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York.
On September 13, 2022, at 7:20 AM ET, CEO Stephen Gunstream and CFO Matt Lowell will engage in a fireside chat discussing company highlights, product portfolio, and market trends. A live audio webcast will be available on Teknova's Investor Relations website for 90 days post-event.
Alpha Teknova reported a total revenue of $11.7 million for Q2 2022, representing a 41% year-over-year increase. The company maintains a cash position of $64.7 million to support ongoing growth investments and has adjusted its 2022 revenue outlook to $38-42 million. Although they experienced healthy demand, Teknova acknowledges potential revenue slowdown in H2 2022 due to biopharma customers deferring purchases. Gross profit reached $5.2 million, with a 44.9% gross margin, despite increased operating expenses of $11.9 million and a net loss of $6.2 million.
HOLLISTER, Calif., Aug. 01, 2022 – Alpha Teknova, Inc. (Nasdaq: TKNO) announced it will report its financial results for Q2 2022 on August 10, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Teknova specializes in providing critical reagents for drug therapies, vaccines, and diagnostics, aiming to expedite clinical breakthroughs with a focus on custom solutions and fast delivery. Its products are essential across various applications, including cell and gene therapy and mRNA therapeutics.
Alpha Teknova, a provider of critical reagents for drug therapies and molecular diagnostics, will participate in the William Blair 42nd Annual Growth Stock Conference from June 6 to 9, 2022, in Chicago, IL. CEO Stephen Gunstream and CFO Matt Lowell will present on June 8 at 4:20 p.m. ET, discussing the company’s highlights, product portfolio, and market opportunities. A live audio webcast will be available on their Investor Relations website for 90 days post-event.
In Q1 2022, Teknova reported total revenue of $11.1 million, a 23% increase year-over-year. Excluding Sample Transport revenue, the increase was 37%. The company achieved a cash position of $76.5 million, supporting its growth strategy and expansion efforts, including a new manufacturing facility expected to be operational by year-end. However, the company reported a net loss of $5.5 million and operating expenses that rose to $11.2 million, reflecting increased hiring and public company costs. The 2022 revenue outlook anticipates $45 million to $48 million.
Alpha Teknova, Inc. (TKNO) will announce its Q1 financial results for the period ending March 31, 2022, on May 11, 2022. A conference call and webcast will occur at 4:30 p.m. ET the same day. The call can be accessed via the Investor Relations section of Teknova's website or by dialing dedicated numbers for domestic and international participants. Teknova specializes in providing critical reagents to support drug therapies, vaccines, and diagnostics, emphasizing customized products for accelerated clinical breakthroughs.
Teknova reported total revenue of $36.9 million for 2021, marking an 18% increase from 2020. Excluding Sample Transport revenue, the total was $35.4 million, up 31%. The fourth quarter revenue was $10.1 million, consistent with 2020, and 26% higher at $9.6 million when excluding Sample Transport. However, the net loss for 2021 was $9.8 million, or $0.61 per diluted share, a decline from 2020's net income. Looking ahead, Teknova projects revenue between $44 million and $48 million for 2022, driven by growth in Lab Essentials and Clinical Solutions.
Alpha Teknova (Nasdaq: TKNO) has announced it will report its financial results for the fourth quarter and full year 2021 on March 15, 2022, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company's performance, focusing on critical reagents for drug therapies and diagnostics. The company is known for its agility in delivering custom products for bioprocessing and molecular diagnostics.